Hikma Pharmaceuticals v Amarin Pharma (U.S., June 4, 2026) 2024-889
This episode concerns the case of Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the Supreme Court addressed whether a generic drug manufacturer can be held liable for active inducement of patent infringement through its marketing and labeling. Amarin alleged that Hikma's "skinny label" and promotional materials encouraged doctors to prescribe its generic drug for a still-patented cardiovascular use, even though the label was only approved for a non-patented indication. The Court unanimously ruled in favor of Hikma, clarifying that active inducement requires affirmative and purposeful…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.